Home   |   Print Page   |   Join MSDC
News & Press: Practice Alerts

DHCF: Removal of Prior Authorization Requirements for Medication-Assisted Treatment Drug Products

Friday, May 17, 2019  
Share |

Removal of Prior Authorization Requirements for Medication-Assisted Treatment Drug Products

The purpose of this transmittal is to replace Transmittal No. 19-11 introducing Policy Number: HCDMA-19-001 which removes the Prior Authorization (PA)  requirements for Medication-Assisted-Treatment (MAT) drug products that are prescribed and dispensed for the treatment of opioid use disorder (OUD) and alcohol use disorder (AUD).

The transmittal states that the policy "permits MAT drug products to be prescribed and dispensed up to the FDA approved maximum daily dose without a PA." See the full transmittal, Transmittal 19-14, for specifications.



Editor's Note: Streamlining prior authorization has long been an MSDC advocacy priority. MSDC argued vigorously for this common-sense, patient-centered measure to combat substance use disorder in the District.   

Association Management Software Powered by YourMembership  ::  Legal